<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="188388">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00641147</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-00536</org_study_id>
    <secondary_id>NCI-2013-00536</secondary_id>
    <secondary_id>CDR0000592794</secondary_id>
    <secondary_id>NA_00011821</secondary_id>
    <secondary_id>00011821</secondary_id>
    <secondary_id>1R01CA134620</secondary_id>
    <secondary_id>R01CA134620</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <nct_id>NCT00641147</nct_id>
  </id_info>
  <brief_title>Curcumin in Treating Patients With Familial Adenomatous Polyposis</brief_title>
  <official_title>Curcumin for Treatment of Intestinal Adenomas in Familial Adenomatous Polyposis (FAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies curcumin in treating patients with familial
      adenomatous polyposis. Curcumin may prevent colorectal cancer in patients with a history of
      rectal polyps or colorectal neoplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine in a randomized, double-blinded, placebo-controlled study the tolerability
      and effectiveness of curcumin to regress intestinal adenomas by measuring duodenal and
      colorectal/ileal polyp number, and polyp size in familial adenomatous polyposis patients
      with intact colons, ileorectal anastomosis surgery, or ileo-anal pullthrough (reservoir)
      surgery.

      II. To measure markers of cell proliferation including colorectal mucosal levels of
      ornithine decarboxylase (ODC), polyamines, mucosal deoxyribonucleic acid (DNA) methylation,
      proliferative index (Ki67 antiproliferative cell nuclear antibody), apoptosis index,
      vascular density, mucosal prostaglandin, leukotriene levels, and activation of the nuclear
      factor kappa B (NFKB), and v-akt murine thymoma viral oncogene homolog 1 (Akt) survival
      pathways.

      OUTLINE: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive curcumin orally (PO) twice daily (BID) for 12 months.

      ARM II: Patients receive placebo PO BID for 12 months.

      After completion of study treatment, patients are followed up at 4 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in activation of NFKB pathway</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Akt phosphorylation levels</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in apoptosis index levels</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Ki-67 anti-proliferative cell nuclear antibody index levels</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in mucosa and adenoma histology assessed by light microscopy</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in mucosal DNA methylation levels</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in mucosal leukotriene levels</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in mucosal prostaglandin levels</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ODC activity levels expressed as nmol of activity/mg of musosal tissue/hr</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in polyamines levels expressed pg/mg protein</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in vascular density</measure>
    <time_frame>Baseline to up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of grade &gt;= 2 adverse events graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>A safety review will be performed at the time of interim analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean polyp size in mm (mean size of the 5 largest polyps)</measure>
    <time_frame>Up to 16 months</time_frame>
    <description>Continuous variables relating to colorectal proliferation and polyp size will be compared in the two treatment groups by parametric statistics.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Medication compliance</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients failing study</measure>
    <time_frame>Up to 16 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Side effects of curcumin treatment</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total number of polyps</measure>
    <time_frame>Up to 16 months</time_frame>
    <description>The average number of polyps in the treatment groups will be compared by the t-test (or a distribution free analog if distribution assumptions are not met). Multivariate regression models will be used to adjust for strongly predictive factors that are not balanced in the treatment groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Familial Adenomatous Polyposis</condition>
  <arm_group>
    <arm_group_label>Arm I (curcumin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive curcumin PO BID for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo PO BID for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (curcumin)</arm_group_label>
    <other_name>C.I. 75300</other_name>
    <other_name>C.I. Natural Yellow 3</other_name>
    <other_name>Diferuloylmethane</other_name>
    <other_name>Turmeric Yellow</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (curcumin)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with familial adenomatous polyposis who have undergone subtotal colectomy
             with ileorectal anastomosis, total coloctomy with ileo-anal pull through (reservoir),
             and patients with intact colons with 5 or more adenomas in the rectum-sigmoid or
             reservoir

          -  Patients with familial adenomatous polyposis (FAP) and duodenal adenomatous polyposis
             without current lower tract adenomatous polyposis i.e. status/post (s/p) ileostomy

        Exclusion Criteria:

          -  Female patients of childbearing age not on effective birth control

          -  Pregnant women

          -  White blood cell count (WBC) &lt; 3500/ml

          -  Platelet count &lt; 100,000/ml

          -  Blood urea nitrogen (BUN) &gt; 25mg%

          -  Creatinine &gt; 1.5mg%

          -  Patients unable to stop non-steroidal anti-inflammatory drugs (NSAIDs), aspirin,
             curcumin, tumeric, calcium, vitamin D, green tea, or polyphenol E supplements for the
             duration of the trial

          -  Malignancy other than nonmelanoma skin cancer

          -  Active bacterial infection

          -  Patients with symptoms of active gastroesophageal reflux disease (GERD) (symptomatic
             despite medication or current erosive esophagitis on endoscopy)

          -  Patients with a history of peptic ulcer disease

          -  Patients on warfarin or plavix
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francis Giardiello</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University/Sidney Kimmel Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Puerto Rico</name>
      <address>
        <city>San Juan</city>
        <zip>00936</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 13, 2016</lastchanged_date>
  <firstreceived_date>March 17, 2008</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Adenomatous Polyposis Coli</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
